17 news items
Needham Maintains Buy on Jazz Pharmaceuticals, Lowers Price Target to $210
JAZZ
20 Jun 24
Needham analyst Ami Fadia maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and lowers the price target from $222 to $210.
Actinium Pharmaceuticals (ATNM) Reveals Promising Results from SIERRA Trial at EHA Congress
ATNM
BMRN
EXEL
17 Jun 24
Pharmaceuticals is dedicated to advancing targeted radiotherapies to significantly enhance survival outcomes for patients who have exhausted conventional
MAIA Biotechnology (MAIA): Pioneering New Frontiers in NSCLC Treatment with THIO
BMRN
EXEL
GMAB
7 Jun 24
. (NYSE:MAIA), a trailblazer in clinical-stage biopharmaceuticals focusing on targeted immunotherapies
This Old Dominion Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
JAZZ
ODFL
PRLB
5 Jun 24
(NASDAQ:TWST) with a Buy rating, while announcing a price target of $53. Twist Bioscience shares gained 6.8% to close at $46.98 on Tuesday
Decoding 12 Analyst Evaluations For Jazz Pharmaceuticals
JAZZ
5 Jun 24
0
Analysts have set 12-month price targets for Jazz Pharmaceuticals, revealing an average target of $198.25, a high
id446fgqdqgol22c8m878l9wmk
JAZZ
5 Jun 24
Goldman Sachs analyst Madhu Kumar initiates coverage on Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy rating and announces Price Target of $169.
32vui6lb8cbcdyxg9sdf680le6ntus1lc4pp6d40pcbn o0xeatp
JAZZ
1 Jun 24
2 (HER2)-targeted bispecific antibody being studied in multiple solid tumors.
For the trial's primary
8of 17wz3tcp
JAZZ
29 May 24
epidermal growth factor receptor 2 (HER2)-targeted bispecific antibody, for the treatment of previously treated, unresectable, locally advanced
5sq811jenzcju63te8t2nyjbg9wf tylzy71twc
JAZZ
29 May 24
Target Action (PDUFA) Date set
9072xqpg6n9vw8abulphsp1zv77o5
AMGN
CASI
JAZZ
7 May 24
accelerated approval to full approval for the treatment of IgAN in the U.S. with a PDUFA target action date of September 5, 2024
prt8hq3eh5bmqo53ju7io89i6mizgr9nuua0f hxnj2yq6mb8x1
JAZZ
3 May 24
HC Wainwright & Co. analyst Oren Livnat reiterates Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and maintains $200 price target.
x1qdo 5t52443gbj
JAZZ
3 May 24
Barclays analyst Balaji Prasad maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and lowers the price target from $230 to $200.
wky15p32c4tnjd
JAZZ
2 May 24
0
Analysts provide deeper insights through their assessments of 12-month price targets, revealing
2bmcd3f6i393v7buaob1amvpx0ne4b29446dbqa7
JAZZ
2 May 24
Needham analyst Ami Fadia reiterates Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Buy and maintains $222 price target.
ysm0wlsprdfeniri9y60g6fizfq509889mc
JAZZ
24 Apr 24
, a HER2-targeted bispecific, biparatopic antibody, in previously treated HER2-positive biliary tract cancer (BTC). Data from the HERIZON-BTC-01 trial
8e2o 5ewsph72a
JAZZ
10 Apr 24
0
Analysts have recently evaluated Jazz Pharmaceuticals and provided 12-month price targets. The average target
wxgrq2mbcu1fveweod nkkxlvukpm395gd6cxmmsh4
JAZZ
10 Apr 24
Cantor Fitzgerald analyst Charles Duncan reiterates Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and maintains $180 price target.
- Prev
- 1
- Next